ACH-3102: Additional Phase II data

Additional data from 12 treatment-naive patients with HCV genotype 1 infection in the open-label, partial-crossover Phase II proxy study showed that once-daily 50 mg ACH-3102 plus 400 mg Sovaldi sofosbuvir for 6 weeks led to an SVR 4 weeks after the end of treatment in 100% of patients. No post-treatment viral relapses were observed. Achillion previously reported data from patients who received the combination for 8 weeks (see BioCentury, Aug. 18, 2014; Oct. 13, 2014 & Nov. 17, 2014). ...